FINWIRES · TerminalLIVE
FINWIRES

Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials

By

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) has secured clearance from China's drug regulator to begin clinical trials for its SHR-3079 injection to treat adult systemic lupus erythematosus and adult rheumatoid arthritis.

There are currently no similar drugs approved for marketing globally, the company said in a Shanghai bourse filing on Tuesday.

The drug is also already in Phase I trials for B-cell non-Hodgkin's lymphoma.

Hengrui has invested about 24.4 million yuan in the project to date.

Related Articles

Asia

Claimants Withdraw Lawsuit Against PropNex's Arm

PropNex (SGX:OYY) said a lawsuit filed against the company's wholly-owned subsidiary, PropNex Realty, as a co-defendant, has been dropped, according to a Friday filing to the Singapore stock exchange.The claimants have discontinued and withdrawn the suit, the statement said.PropNex Realty was named as one of three co-defendants in a lawsuit filed in the High Court of Singapore in February. According to the lawsuit, claimants sought damages against PropNex Realty for alleged breach of duty of care and sought compensation of around SG$367,405 in damages.The withdrawal of the case is not expected to have any material impact on the financial position and performance of the group for the financial year ending Dec. 31.PropNex's shares were down nearly 1% in Monday's trade.

SGX:OYY
Asia

Dawning Information Industry Proposes Convertible Bond Issue for AI, Storage Push

Dawning Information Industry (SHA:603019) on Monday filed a prospectus for a convertible bond issue to unspecified investors.Proceeds are earmarked toward an artificial intelligence computing cluster system, a next-generation AI training-inference integrated machine and a domestic advanced storage system.Shares of the supercomputer manufacturer were down 1% in recent trade.

SHA:603019
Asia

Ampol Secures KKR as Cornerstone Investor in AU$400 Million Financing Transaction; Shares Up 3%

Ampol (ASX:ALD) secured a cornerstone investment from KKR in its AU$400 million financing transaction, according to a Monday statement from the investment firm.KKR is making this investment from its Asia Pacific Credit strategy and insurance platform, with support from Clifford Capital.Ampol will use the funds for refinancing initiatives and other general corporate purposes.Ampol's shares rose nearly 3% in recent trading on Monday.

ASX:ALD